PD-1 mAb (29F.1A12)™, InVivoPure

ID: AK3613P Category:

The 29F.1A12 antibody is a monoclonal antibody directed against the mouse protein PD-1 (Programmed Death-1), also known as CD279. It blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2.

This antibody is produced exclusively under serum-free conditions from hybridoma and purified with Protein-A or Protein-G affinity chromatography.

In stock

Delivery time: 2-5 days

From: 140,00 € Excl. VAT and delivery costs

Please contact us for larger quantities.

Endotoxin level ≤ 2 EU/mg

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and
plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed
death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation.
Moreover abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the
tumor microenvironment mediates tumor immune escape, and the development of anti-PD-
1/PD-L1 antibodies has recently become a hot topic in cancer immunotherapy.

The 29F.1A12 antibody is a monoclonal antibody directed against the mouse protein PD-1
(Programmed Death-1), also known as CD279. It blocks the binding of PD-1 to its two ligands,
PD-L1 and PD-L2.

This antibody is produced exclusively under serum-free conditions from hybridoma and
purified with Protein-A or Protein-G affinity chromatography.

 

 

Product-ID: AK3613P
Clone: 29F.1A12
Immunogen: The antibody was raised by immunizing rats with plasmid DNA containing PD-1. Boost immunizations were done with PD-1-Igfusion proteins.
Host: Rat
Clonality: Monoclonal
Isotype: Rat IgG2a ĸ
Formulation: Clear Liquid, PBS, pH 7.4, 0.2 μm sterile filtered
Concentration: ≥ 1.00 mg/mL
Purity: ≥ 90 % (CGE, reducing conditions)
≤ 10 % aggregates (analytical SEC)
Endotoxin: ≤ 2 EU/mg (LAL test)
Storage: 2 - 8 °C

 

The product is for research use only and not for use in diagnostic or therapeutic procedures.

Additional information

Literature

[1] Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future
considerations. Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub
2019 Mar 19. PMID: 30888929; PMCID: PMC6605868.
[2] Chen L, Sham CW, Chan AM, Francisco LM, Wu Y, Mareninov S, Sharpe AH, Freeman GJ, Yang XJ, Braun J,
Gordon LK. Role of the immune modulator programmed cell death-1 during development and apoptosis of
mouse retinal ganglion cells. Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4941-8. doi: 10.1167/iovs.09-3602.
Epub 2009 May 6. PMID: 19420345; PMCID: PMC3222380.
[3] Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW,
McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is
enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul;2(7):643-54. doi:
10.1158/2326-6066.CIR-13-0215. Epub 2014 Apr 29. PMID: 24903021; PMCID: PMC4097121.
[4] Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH. Regulation of PD-1,
PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003
Oct;33(10):2706-16. doi: 10.1002/eji.200324228. PMID: 14515254.
Document

Product Information Sheet – AK3613P
Notice

The product is for research use only and not for use in diagnostic or therapeutic procedures.

Reviews

There are no reviews yet.

Be the first to review “PD-1 mAb (29F.1A12)™, InVivoPure”